Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Comparative Efficacy and Safety of Daratumumab in Combination with Bortezomib, Melphalan, and Prednisone (D-VMP) in Alcyone Versus Bortezomib, Melphalan, and Prednisone (VMP) in Vista in Newly Diagnosed Multiple Myeloma (NDMM) Patients Using Propensity Score Matching (PSM)

Michele Cavo, MD, Meletios A Dimopoulos, MD, Jesus F San-Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Andrzej Jakubowiak, MD PhD, William Deraedt, Annette Lam, Tobias Kampfenkel, MD, Ming Qi, MD PhD, Jianming He, PhD

Blood (2018) 132 (Supplement 1): 3550.

https://doi.org/10.1182/blood-2018-99-113128

Published: 2018

Journal Articles

Impact of Modified Dose Schedule of Bortezomib, Melphalan, and Prednisone (VMP) for Previously Untreated, Transplant-Ineligible Patients with Multiple Myeloma (MM): A Matching-Adjusted Indirect Comparison

Jesus F San-Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Hartmut Goldschmidt, MD, Pieter Sonneveld, MD PhD, Meletios A Dimopoulos, MD, Bart Heeg, PhD, Mahmoud Hashim, William Deraedt, Peter Hu, Annette Lam, Jianming He, PhD

Blood (2018) 132 (Supplement 1): 3553.

https://doi.org/10.1182/blood-2018-99-113157

Published: 2018

Journal Articles

Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)

Blood (2017) 130 (Supplement 1): 3121.

https://doi.org/10.1182/blood.V130.Suppl_1.3121.3121

Published: 2017

Journal Articles

The Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients

Naoki Takezako, MD PhD, Michihide Tokuhira, MD PhD, Naohiro Sekiguchi, MD PhD, Yuya Kurihara, MD, Kenichi Ito, MD, Miwa Kurimoto, MD PhD, Kenshi Suzuki, MD PhD, Masahiro Kizaki, MD PhD

Blood (2016) 128 (22): 4529.

https://doi.org/10.1182/blood.V128.22.4529.4529

Published: 2016

Journal Articles

Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma

Maximilian Merz, MD, Hans-Juergen Salwender, MD, Mathias Haenel, MD, Uta Bertsch, MD, Christina Kunz, Thomas Hielscher, Igor W. Blau, MD, Christof Scheid, MDPhD, Elias Karl Mai, MD, Dirk Hose, MD, Bärbel Schurich, Markus Munder, MD, Peter Brossart, MD, Christian Gerecke, MD, Hans Walter Lindemann, MD, Matthias Zeis, MD, Katja C. Weisel, Jan Duerig, MD, Hartmut Goldschmidt, MD

Blood (2015) 126 (23): 4233.

https://doi.org/10.1182/blood.V126.23.4233.4233

Published: 2015

Journal Articles

Which Should be Pursued, Cumulative Dose or Dose Intensity: A Real-World Effectiveness Analysis of Bortezomib-Based First Line Treatment for Untreated Multiple Myeloma Patients

Shenmiao Yang, MD, Aijun Liu, MD, Yuping Zhong, MD, Xiaojun Huang, MDPhD, Wenming Chen, MD, Jin Lu

Blood (2015) 126 (23): 4247.

https://doi.org/10.1182/blood.V126.23.4247.4247

Published: 2015

Journal Articles

Interim Analysis of Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma.

Tadao Ishida, MD, Hideo Kimura, MD PhD, Koumei Kubo, MD, Kazutaka Sunami, MD, Shuji Ozaki, MD, Naoki Takezako, MD, Hiroshi Handa, MD PhD, Hiroshi Kosugi, MD, Hirokazu Murakami, MD, Kazuyuki Shimizu, MD

Blood (2015) 126 (23): 3043.

https://doi.org/10.1182/blood.V126.23.3043.3043

Published: 2015

Journal Articles

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

Blood (2013) 122 (21): 3187.

https://doi.org/10.1182/blood.V122.21.3187.3187

Published: 2013

Journal Articles

Carfilzomib PLUS Melphalan and Prednisone (CMP) Is A Promising Combination Therapy For The Treatment Of Elderly Patients With NEWLY Diagnosed Multiple Myeloma: Results Of A PHASE I/II Trial In 68 CASES

Philippe Moreau, MD, Brigitte Kolb, MD, Cyrille Hulin, MD, Denis Caillot, MD, Lotfi Benboubker, MD, Mourad Tiab, MD, Cyrille Touzeau, Xavier Leleu, MD, PhD, Murielle Roussel, MD, Carine Chaleteix, MD, Michel Attal, MD, Thierry Facon, MD

Blood (2013) 122 (21): 1933.

https://doi.org/10.1182/blood.V122.21.1933.1933

Published: 2013

Journal Articles

Observational Study Of VMP (Bortezomib, melphalan, prednisolone) Regimen For Newly Diagnosed Korean Myeloma Patients Who Are Not Eligible For Transplantation

Blood (2013) 122 (21): 5379.

https://doi.org/10.1182/blood.V122.21.5379.5379

Published: 2013

Journal Articles

A Phase I/II Study of Bortezomib in Combination with Melphalan and Prednisolone in Japanese Patients with Newly Diagnosed Multiple Myeloma

Kenshi Suzuki, MD, PhD, Kiyoshi Ando, MD, PhD, Akira Sakai, MD, PhD, Shinsuke Iida, MD, PhD, Michinori Ogura, Kensei Tobinai, MD, PhD, Morio Matsumoto, MD, Kosei Matsue, MD, PhD, Yasuhito Terui, MD, PhD, Kazuteru Ohashi, MD, Takaaki Chou, MD, PhD, Kazutaka Sunami, MD, PhD, Atsushi Shinagawa, MD, Nobuyuki Aotsuka, MD, PhD, Hirohiko Shibayama, MD, PhD, Takayuki Takahashi, MD, PhD, Harumi Yamamoto Mukai, MD, PhD, Tomomitsu Hotta, MD, PhD

Blood (2011) 118 (21): 5132.

https://doi.org/10.1182/blood.V118.21.5132.5132

Published: 2011

Journal Articles

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Blood (2011) 118 (21): 476.

https://doi.org/10.1182/blood.V118.21.476.476

Published: 2011

Journal Articles

Optimal Treatment Sequencing In Multiple Myeloma: An Exploratory Modeling Approach

Bart Heeg, Michel van Agthoven, Johan Liwing, Ulf-Henrik Mellqvist, Torben Plesner, Floris Logman, Verena Donatz, Johan Aschan, Hermann Einsele, Martin Kropff, Maarten Treur, Mirjam Barendse, Jean-Luc Harousseau, Antonio Palumbo, Pieter Sonneveld

Blood (2010) 116 (21): 3046.

https://doi.org/10.1182/blood.V116.21.3046.3046

Published: 2010

Journal Articles

Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination

Blood (2010) 116 (21): 309.

https://doi.org/10.1182/blood.V116.21.309.309

Published: 2010

Journal Articles

The Cost-Effectiveness of Bortezomib Plus Melphalan and Prednisone Versus Lenalidomide Plus Melphalan and Prednisone with Continuous Lenalidomide Maintenance Treatment for the Initial Treatment of Multiple Myeloma In the United States

Si-Tien Wang, MS, Hui Huang, PhD, MBA, Abbie Ba-Mancini, BS, MBA, Hongliang Shi, MS, Kristina Chen, MS, Caroline Korves, ScD, Ravinder Dhawan, PhD, Andrew Cakana, FRCPath, MD, Helgi van de Velde, Dixie-Lee W. Esseltine, MD, FRCPC, Mei S. Duh, ScD, MPH

Blood (2010) 116 (21): 2563.

https://doi.org/10.1182/blood.V116.21.2563.2563

Published: 2010

Journal Articles

No longer the poor relations

Andrew Spencer

Blood (2010) 116 (19): 3685–3686.

https://doi.org/10.1182/blood-2010-07-297556

Published: 2010

Journal Articles

More force or more smart?

Pieter Sonneveld

Blood (2010) 115 (10): 1859–1860.

https://doi.org/10.1182/blood-2009-12-258830

Published: 2010

Journal Articles

The Cost-Effectiveness of Bortezomib for the Initial Treatment of Multiple Myeloma in the United States.

Si-Tien Wang, Hui Huang, Hongliang Shi, Mei Sheng Duh, Kristina Chen, Eva Chang, Caroline Korves, Ravinder Dhawan, Andrew Cakana, Helgi van de Velde, Dixie-Lee Esseltine, Louis Garrison

Blood (2009) 114 (22): 1379.

https://doi.org/10.1182/blood.V114.22.1379.1379

Published: 2009

Journal Articles

Sustained Health-Related Quality of Life (HRQoL) Improvement in Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib/Melphalan/Prednisone Versus Melphalan/Prednisone: Results From the VISTA Trial.

Ravinder Dhawan, Don Robinson Jr., Juliette Meunier, Antoine Regnault, Kathleen Rosa, Andrew Z Cakana, Helgi van de Velde, Paul G Richardson, Jesús F San Miguel

Blood (2009) 114 (22): 1881.

https://doi.org/10.1182/blood.V114.22.1881.1881

Published: 2009

Journal Articles

Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.

Blood (2009) 114 (22): 3859.

https://doi.org/10.1182/blood.V114.22.3859.3859

Published: 2009

NARROW

Comparative Efficacy and Safety of Daratumumab in Combination with Bortezomib, Melphalan, and Prednisone (D-VMP) in Alcyone Versus Bortezomib, Melphalan, and Prednisone (VMP) in Vista in Newly Diagnosed Multiple Myeloma (NDMM) Patients Using Propensity Score Matching (PSM)

Impact of Modified Dose Schedule of Bortezomib, Melphalan, and Prednisone (VMP) for Previously Untreated, Transplant-Ineligible Patients with Multiple Myeloma (MM): A Matching-Adjusted Indirect Comparison

Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)

The Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients

Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma

Which Should be Pursued, Cumulative Dose or Dose Intensity: A Real-World Effectiveness Analysis of Bortezomib-Based First Line Treatment for Untreated Multiple Myeloma Patients

Interim Analysis of Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma.

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

Carfilzomib PLUS Melphalan and Prednisone (CMP) Is A Promising Combination Therapy For The Treatment Of Elderly Patients With NEWLY Diagnosed Multiple Myeloma: Results Of A PHASE I/II Trial In 68 CASES

Observational Study Of VMP (Bortezomib, melphalan, prednisolone) Regimen For Newly Diagnosed Korean Myeloma Patients Who Are Not Eligible For Transplantation

A Phase I/II Study of Bortezomib in Combination with Melphalan and Prednisolone in Japanese Patients with Newly Diagnosed Multiple Myeloma

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Optimal Treatment Sequencing In Multiple Myeloma: An Exploratory Modeling Approach

Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination

The Cost-Effectiveness of Bortezomib Plus Melphalan and Prednisone Versus Lenalidomide Plus Melphalan and Prednisone with Continuous Lenalidomide Maintenance Treatment for the Initial Treatment of Multiple Myeloma In the United States

No longer the poor relations

More force or more smart?

The Cost-Effectiveness of Bortezomib for the Initial Treatment of Multiple Myeloma in the United States.

Sustained Health-Related Quality of Life (HRQoL) Improvement in Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib/Melphalan/Prednisone Versus Melphalan/Prednisone: Results From the VISTA Trial.

Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only